Search

Your search keyword '"LUND, MAYANNA"' showing total 169 results

Search Constraints

Start Over You searched for: Author "LUND, MAYANNA" Remove constraint Author: "LUND, MAYANNA"
169 results on '"LUND, MAYANNA"'

Search Results

1. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF

7. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial

8. NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories

9. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

10. Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure.

12. 2023 position statement on improving management for patients with heart failure in Aotearoa New Zealand

13. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes

17. LONGITUDINAL CHANGES IN N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE: ASSOCIATIONS WITH ECHOCARDIOGRAPHIC CHANGES AND OUTCOMES IN HEART FAILURE FROM THE SHOP AND PEOPLE STUDY

19. Titration of medications and outcomes in multi‐ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand

22. The Singapore Heart Failure Outcomes and Phenotypes (SHOP) Study and Prospective Evaluation of Outcome in Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PEOPLE) Study: Rationale and Design

23. Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure

24. Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure

25. 41 Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure

27. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype

29. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

30. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

31. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction:GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

32. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

33. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

36. Cardiovascular disease and COVID ‐19: Australian and New Zealand consensus statement

37. Contrasting trends in heart failure incidence in younger and older New Zealanders, 2006-2018.

39. Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific

42. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study

Catalog

Books, media, physical & digital resources